Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36905345/
We assessed the effect of semaglutide 2.4 and 1.7 mg versus placebo on weight-related quality of life (WRQOL) and health-related quality of life (HRQOL) in the STEP 6 trial. Adults from East Asia (body mass index [BMI] ≥27.0 kg/m 2 with ≥2 weight-related comorbidities, or ≥35.0 kg/m 2 ...
Conclusion: Overweight and obesity can have a negative impact on WRQOL and HRQOL. Our results demonstrate that in people from East Asia with overweight or obesity, treatment with once-weekly subcutaneous semaglutide 2.4 mg, in addition to a reduced caloric diet and increased physical activity, improved aspects of WRQOL and HRQOL, including the ability to perform daily activities.
Share
• Source: Clinical Obesity
• Conclusions/Relevance: “Treatment with semaglutide 2.4 mg improved aspects of WRQOL [work-related quality of life] and HRQOL [health-related quality of life] in people from East Asia with overweight/obesity.”
• In the current study, international researchers included 401 adults from East Asia who were randomized 4:1:2:1 to receive once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
• Semaglutide 2.4 mg resulted in weight loss and improved facets (i.e., trending towards significance) of WRQOL and HRQOL, such as the ability to perform daily activities.
• “While the patient population of the present analysis is smaller than in the global trials, this is the first report of the effects of a GLP-1RA for weight management in people from East Asia. However, the STEP 6 trial was not powered to show treatment differences in patient-reported outcomes, and although treatment effects tended to favour semaglutide compared with placebo, there were too few patients in the trial to obtain statistically significant results,” the authors wrote.